Brickell Bio Invested 2019

In July 2019, Brickell successfully completed a merger with Vical Incorporated (Nasdaq:VICL) in an all-stock transaction, creating a liquidity event for VisionTech Angels investors. The combined company operates as Brickell Biotech, Inc. and trades on the Nasdaq Capital Market. Brickell Bio is a clinical stage pharmaceutical company focused on developing innovative and differentiated therapeutics for treating skin diseases. Brickell’s lead pipeline asset, sofpironium bromide, is a pivotal Phase 3-ready topical soft anticholinergic intended for axillary hyperhidrosis (chronic excessive perspiration). The company’s pipeline also includes potential novel therapeutics for cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. www.Brickellbio.com


Looking for Funding?

VisionTech Partners may be able to help. Through VisionTech Angels and a broad network of investors and business resources, our goal is to help promising ventures succeed. We focus on early stage and early growth technology-based companies in Indiana and the Midwest.

If you have questions or would like more information, Contact Us. If you’re ready to start the process, Submit Your Business Plan using the secure website of Gust, the global platform for angel investing. We look forward to hearing from you!